Oncology
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies Initial clinical data anticipated in 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the Company has submitted the investigational new drug (IND)…
Read More
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors Excerpt from the Press Release: SAN DIEGO,…
Read More
Excerpt from the Press Release: PALO ALTO, Calif. & DALLAS–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast…
Read More
– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC – – With Median Follow-Up of Approximately 12 Months, Both Domvanalimab-Containing Study Arms Also Improved ORR and Six-Month Landmark PFS Compared to Zimberelimab Monotherapy – –…
Read More
Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer (CRC) in average-risk…
Read More
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T’s) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presentation of the clinical data at the Immuno-Oncology 360° conference in February 2023 Excerpt from the Press…
Read More Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San…
Read More
— Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML — No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax — ALX Oncology to Host Conference Call on December 13th at 7:30 a.m. EST Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 12,…
Read More
Excerpt from the Press Release: Collaboration employing Guardant360 CDx assay is first to use ctDNA comprehensive genomic profiling blood test for early detection of resistance due to ESR1 mutation prior to first-line therapy progression PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration…
Read More